Wugen Revenue and Competitors
Estimated Revenue & Valuation
- Wugen's estimated annual revenue is currently $15.2M per year.
- Wugen's estimated revenue per employee is $155,000
- Wugen's total funding is $172M.
Employee Data
- Wugen has 98 Employees.
- Wugen grew their employee count by -6% last year.
Wugen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Clinical Operations | Reveal Email/Phone |
3 | VP, Finance and Business Operations | Reveal Email/Phone |
4 | Director Translational Research | Reveal Email/Phone |
5 | Associate Director, Operational Excellence | Reveal Email/Phone |
6 | Sr. Director, Head Supply Chain & Procurement | Reveal Email/Phone |
7 | Chief Medical Officer | Reveal Email/Phone |
8 | Director Discovery | Reveal Email/Phone |
9 | Associate Director | Reveal Email/Phone |
10 | Director, Regulatory Affairs | Reveal Email/Phone |
Wugen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $79.1M | 510 | 6% | N/A | N/A |
#2 | $1.1M | 7 | 17% | N/A | N/A |
#3 | $4.2M | 27 | -32% | N/A | N/A |
#4 | $2M | 13 | 30% | N/A | N/A |
#5 | $4.3M | 28 | 4% | N/A | N/A |
#6 | $0.9M | 6 | 0% | N/A | N/A |
#7 | $5M | 32 | 3% | N/A | N/A |
#8 | $3.7M | 24 | 4% | N/A | N/A |
#9 | $0.3M | 4 | 0% | N/A | N/A |
#10 | $6M | 39 | 50% | N/A | N/A |
What Is Wugen?
An "Off-the-Shelf" Fratricide Resistant CAR-T for the treatment of T-cell hematologic malignancies
keywords:N/A
$172M
Total Funding
98
Number of Employees
$15.2M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Wugen News
Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies...
Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) and CAR-T cell...
ST. LOUIS St. Louis-based clinical-stage biotechnology startup Wugen, which has raised more than $200 million in venture funding,...
San Diego-based Wugen, a biotechnology company which is developing treatments for solid tumors, recently annoucned a $172M, Series B funding round. The company--which says it licensed its technology from Washington University in St. Louis--said the Series B was co-led by Abingworth and Tybourne ...
Wugen, a Sant Louis MO- and San Diego CA-based clinical stage biotechnology company, raised $172M in Series B funding. The round was led by Abingworth and Tybourne Capital Management with participation from Fidelity Management & Research Company, Intermediate Capital Group (ICG), Sands Capital, ...
Other Companies in St Louis
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 101 | 44% | N/A |
#2 | $3.5M | 104 | 58% | N/A |
#3 | $34.1M | 105 | 4% | N/A |
#4 | $14.8M | 106 | -4% | $61.5M |
#5 | $15.4M | 106 | -2% | N/A |